The estimated Net Worth of Kim P. Kamdar is at least $253 mil dollars as of 18 June 2021. Kim Kamdar owns over 10,000 units of Evofem Biosciences Inc stock worth over $174 and over the last 9 years he sold EVFM stock worth over $3,327. In addition, he makes $249,900 as Independent Director at Evofem Biosciences Inc.
Sign up
Kim Kamdar EVFM stock SEC Form 4 insiders trading
Kim has made over 7 trades of the Evofem Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 10 units of EVFM stock worth $6 on 21 December 2023.
The largest trade he's ever made was buying 54,945 units of Evofem Biosciences Inc stock on 23 August 2018 worth over $100,000. On average, Kim trades about 4,196 units every 114 days since 2015. As of 18 June 2021 he still owns at least 19,287 units of Evofem Biosciences Inc stock.
You can see the complete history of Kim Kamdar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kim Kamdar biography
Dr. Kim P. Kamdar Ph.D. serves as Independent Director of the Company. Dr. Kamdar is a Managing Partner of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005.Dr. Kamdar is currently Chair of the Board of Directors of Aspen Neuroscience, Seraphina Therapeutics, Inc. and Truvian Sciences. She also serves on the Board of Directors of several private companies including Epic Sciences, Obalon Therapeutics, Omniome, Sera Prognostics and Singular Genomics. Past investments include Ariosa (acquired by Roche), Corthera (acquired by Novartis), BiPar Sciences (acquired by Sanofi-Aventis) and Achaogen (Nasdaq: AKAO). Formerly, Dr. Kamdar was a Kauffman Fellow with MPM Capital (MPM). Prior to joining MPM, Dr. Kamdar was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents. Dr. Kamdar received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. Dr. Kamdar serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and is also on the non-profit board for Access Youth Academy, an organization that is transforming the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash. Kamdar is qualified to serve on our Board of Directors based on her extensive experience working and serving on the boards of directors of life sciences companies and her experience working in the venture capital industry.
What is the salary of Kim Kamdar?
As the Independent Director of Evofem Biosciences Inc, the total compensation of Kim Kamdar at Evofem Biosciences Inc is $249,900. There are 12 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of $2,803,980.
How old is Kim Kamdar?
Kim Kamdar is 52, he's been the Independent Director of Evofem Biosciences Inc since 2018. There are 9 older and 5 younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.
What's Kim Kamdar's mailing address?
Kim's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 7770 REGENTS RD, SUITE 113-618, SAN DIEGO, CA, 92122.
Insiders trading at Evofem Biosciences Inc
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link y Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
What does Evofem Biosciences Inc do?
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
What does Evofem Biosciences Inc's logo look like?
Complete history of Kim Kamdar stock trades at Obalon Therapeutics Inc, Syndax Pharmaceuticals Inc y Evofem Biosciences Inc
Evofem Biosciences Inc executives and stock owners
Evofem Biosciences Inc executives and other stock owners filed with the SEC include:
-
Saundra Pelletier,
President, Chief Executive Officer, Director -
Kelly Culwell,
Chief Medical Officer -
Saundra Pelletier,
Pres, CEO & Director -
Thomas Lynch,
Chairman of the Board -
Russell Barrans,
Chief Commercial Officer -
Justin File,
Chief Financial Officer -
Justin J. File,
Chief Financial Officer -
Russell Barrans,
Chief Commercial Officer -
Tony O'Brien,
Independent Director -
William Hall,
Independent Director -
Colin Rutherford,
Independent Director -
Gillian Greer,
Independent Director -
Kim Kamdar,
Independent Director -
Amy Raskopf,
IR Contact Officer -
Lisa Rarick,
Independent Director -
Alexander Fitzpatrick,
Executive Vice President, General Counsel, Secretary -
Dr. Kelly Culwell M.D.,
Chief Medical Officer -
Kathy Gallo-Doyle,
VP of Sales -
Alexander A. Fitzpatrick Esq.,
Exec. VP, Gen. Counsel & Sec. -
Biopharma, Inc. Pdl,
10% owner -
Research Corp Acacia,
10% owner -
Anthony Stephen O'brien,
Director -
Yan Zhang,
CFO -
Ltd. Invesco,
10% owner -
Fund Solutions Ltd Link,
10% owner